NCT00054873已完成2 期
Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 58
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of tezacitabine when given alone or in combination with 5-fluorouracil (5-FU) to subjects who have advanced esophageal or gastric adenocarcinoma.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females greater than or equal to 18 years of age.
- •Histologically confirmed recurrent (inoperable) or metastatic adenocarcinoma of the esophagus, gastroesophageal junction, or stomach.
- •At least one bidimensionally measurable lesion, not previously irradiated, with a diameter that meets RECIST criteria, that can be serially measured. Intraluminal tumors, evaluable only by endoscopy, are not acceptable as target lesions.
- •Karnofsky Performance Score greater than or equal to 70%.
- •Subjects must be in the second line therapy setting, thus they must have experienced progression following treatment with one (and only one) prior chemotherapy regimen used for the treatment of unresectable locally advanced, recurrent, or metastatic disease.
- •Recovery from any serious (grade 3 or higher) toxic effects of prior radiation therapy.
- •Adequate hematologic profile: absolute neutrophil count greater than or equal to 1,500/mm3; hemoglobin greater than or equal to 9 g/dL; hematocrit greater than or equal to 30% (transfusion allowed); and platelet count greater than or equal to 100,000/mm
- •Adequate hepatic function: bilirubin less than or equal to 1.5 mg/dL; AST and ALT less that 2.5 X ULN (5 X ULN if liver involved with tumor); alkaline phosphatase less than 5 X ULN
- •Adequate renal function; serum creatinine less than or equal to 1.5 mg/dL or calculated creatinine clearance greater than 50 mL/min.
- •Both male and female subjects of childbearing potential must be using a contraceptive method that is medically acceptable to the investigative center.
- •Disease-free from a prior malignancy, other than non-melanoma skin cancer or carcinoma in-situ of the cervix, for greater than 5 years.
排除标准
- •Unstable angina or class III or IV New York Heart Association heart disease.
- •CNS metastases.
- •Pregnant or breast-feeding.
- •Uncontrolled seizure disorder.
- •Ongoing (grade 3 or higher) stomatitis, esophagopharyngitis, or uncontrolled diarrhea.
- •Impaired nutritional status as evidenced by a serum albumin of 2.7 mg/dL or less.
- •Major surgery, chemotherapy, immunotherapy, or radiotherapy during the 28 days preceding the first study treatment. Concomitant anticancer therapy (chemotherapy, immunotherapy, or radiation) or other investigational agents during study participation or 28 days prior to study participation.
研究者
研究点 (58)
Loading locations...
相似试验
已完成
4 期
effectiveness of tofacitinib in moderate to severe ulcerative colitis compared to steroidCTRI/2023/09/057448Shankar Roy94
已完成
2 期
A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR MutationCystic FibrosisNCT02730208Vertex Pharmaceuticals Incorporated41
已完成
不适用
Combination therapy of 5-Fluorouracil/gemcitabine/cisplatin for advanced hepatocellular carcinoma with extrahepatic metastases -A pilot studyHepatocellular carcinoma with extrahepatic metastasesJPRN-UMIN000000719Hiroshima University5
已完成
2 期
Gemcitabine (GFF) in Patients With Pancreatic CancerMetastatic Pancreatic CancerNCT00919282CONKO-Studiengruppe78
撤回
2 期
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal CancerColorectal CancerNCT00388700Galectin Therapeutics Inc.